Q1 2025 Bausch Health Companies Inc Earnings Call Transcript
Key Points
- Bausch Health Companies Inc (BHC) achieved its eighth consecutive quarter of year-over-year revenue and adjusted EBITDA growth.
- The company successfully completed a $7.9 billion refinancing effort, extending near- and medium-term maturities, providing additional financial flexibility.
- Bausch Health Companies Inc (BHC) received a favorable ruling from the DC District Court in the Norwich case against the FDA.
- The Salix segment showed strong performance with 8% growth in Xifaxan sales, driven by both price and volume increases.
- The Solta Medical segment delivered 33% organic revenue growth, with significant contributions from South Korea and China.
- Adjusted operating cash flow guidance was updated down by $150 million due to higher interest rate expenses from the refinancing transaction.
- Adjusted gross margin decreased by 130 basis points year-over-year.
- The International segment reported a 1% decrease in revenue on a reported basis, impacted by currency fluctuations.
- The company faces potential challenges from evolving tariffs and trade measures, particularly affecting the Solta business in China.
- Despite strong financial performance, Bausch Health Companies Inc (BHC) acknowledges that its stock price does not reflect the company's value, indicating a need to unlock shareholder value.
Greetings. Welcome to the Bausch Health first-quarter 2025 earnings call. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to your host, Garen Sarafian, Investor Relations at Bausch. You may begin.
Good afternoon, and welcome to Bausch Health first-quarter 2025 earnings conference call. Participating in today's call are Thomas Appio, Chief Executive Officer of Bausch Health; and JJ Charhon, Chief Financial Officer.
Before we begin, I would like to remind you that our presentation today contains forward-looking information. We ask you to take a moment to read the forward-looking statements disclaimer at the beginning of the pages that accompany this presentation as it contains important information.
Our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place undue reliance on any forward-looking statements. Please refer to our SEC filings and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
